CUBE LABS S.P.A. - Post author:Admin
- Post published:03/04/2023
- Post category:Senza categoria
Rome, 3 April 2023 - Cube Labs S.p.A., an Italian venture builder in the healthcare technology space, and IBI (Istituto Biochimico Italiano G. Lorenzini Spa), an international biopharmaceutical company specializing in the aseptic manufacturing of injectable medicinal products, have signed a framework agreement for the development and commercialization of healthcare technologies.
The partnership will enable Cube Labs to take a significant stride towards the market, accelerating the scaling-up of Cube Labs' portfolio, and once specific program agreements are defined, grant IBI pre-emption rights over R&D activities, business development at national and international levels, and product commercialization and distribution related to technologies and research developed by Cube Labs' controlled companies. The intellectual and industrial property rights resulting from the execution of the agreement will remain with Cube Labs.
In particular, IBI will operate as an industrial strategic partner for Cube Labs' companies through technical feasibility analyses and commercial agreements to be finalized within the next 24 months. The specific companies will be identified as needed.
IBI entered Cube Labs' share capital during their EGM Pro market listing debut on 21 March.
"We are proud to begin this collaboration with a prestigious company such as IBI Lorenzini, which will accelerate our technology transfer processes from the bench to the market," said Dr. Filippo Surace, CEO and Founder of Cube Labs. "This is another step towards Cube Labs' ultimate mission of transforming academic science into global healthcare solutions".
Dr. Camilla Borghese, CEO and President of the Giovanni Lorenzini Italian Biochemical Institute, emphasized the significance of the collaboration: "IBI is proud and fully committed to this alliance. Our mission for over a century has been to leverage our expertise in drug development and production to provide patients with targeted, effective and safe therapies. We are prepared to take on the technological and scientific challenges that will stem from this collaboration between the scientific, industrial and economic sectors".
***
The official text is the Italian version of the document. Any discrepancies or differences arisen in the translation are not binding and have no legal effect. In case of any dispute on the contents, the Italian original version shall always prevail.
***
Cube Labs
Cube Labs is an Italian venture builder in the healthcare technology sector, created to bridge the gap between excellent academic science in Italy and the commercial life science market. Cube Labs creates new companies from commercially promising R&D and enables innovation to transform pioneering science into healthcare solutions. Through its international network, Cube Labs collaborates with innovation stakeholders to transform outcomes for patients and accelerate the global transition to optimal health. Cube Labs S.p.A. is listed on the Euronext Growth Milan market - Professional Segment.
For further information, please visit: www.cube-labs.com
IBI
IBI (Istituto Biochimico Italiano G. Lorenzini Spa) is a leading international biopharmaceutical company that has been operating since 1918. Specializing in aseptic manufacturing of Injectable Medicinal Products, IBI has established direct commercial presence in the UK, Germany, and Italy, while also exporting through alliances to more than 20 countries worldwide, including the US, Australia, and Europe. IBI offers comprehensive CDMO services, including advanced formulation, process development, and GMP manufacturing of sterile finished products. Their expertise extends to developing solutions and freeze-dried powders for both chemical and biotech active ingredients, such as small molecules, monoclonal antibodies, recombinant proteins, oligonucleotides, and nanoparticle technologies.
For further information, please visit: www.ibi-lorenzini.it.
Cube Labs
Global Media Contact
Isil Guney
Tel: +90 5325027243
E-mail: i.guney@cube-labs.com
Investor Relations
Vincenza Colucci
E-mail: vincenza.colucci@cdr-communication.it
Marika Martinciglio
E-mail: marika.martinciglio@cdr-communication.it
Ufficio Stampa Italia di Cube Labs
Matteo Steinbach
Cell. +393461063989
E-mail: matteo.steinbach@secnewgate.it
Federico Ziglioli
Cell. +393331225959
E-mail: federico.ziglioli@secnewgate.it
IBI Lorenzini
Ufficio Stampa IBI LORENZINI Stefania Testa
Cell. +390692150403
E-mail: stesta@ibi-lorenzini.com
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cube Labs S.p.A. published this content on 03 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 May 2023 13:55:03 UTC.
